The talk will highlight new data demonstrating that oral treatment with ProteoTech's small molecule Systebryl(TM) causes a marked prevention of AA amyloid
fibril formation, and a marked reduction and clearance (by 50-80%) of pre-existing AA amyloid
fibril deposits in a relevant animal model of systemic AA amyloidosis.
Renal AA amyloid
deposition is found in varying degrees between the glomeruli, blood vessels, and interstitium.
There is evidence that AA amyloid
formation can be triggered by other types of amyloid molecule, leading to speculation that amyloid fibrils found in the environment and food could cross-seed amyloid formation in the body or brain.
Professor Hazenberg presented results of a sub-study of the Phase II/III trial to assess the presence/absence of AA amyloid
in abdominal fat tissue in the two treatment groups during the two year trial.
Systemic AA amyloidosis occurs in a small subset of patients with rheumatoid arthritis or other inflammatory diseases, in which AA amyloid
fibril accumulation occurs in systemic organs, including heart, kidney, liver and gastrointestinal tract.